 Home > Active Ingredient News > Drugs Articles > AstraZeneca's 2022Q3 China revenue was $1.541 billion, up another 8%! Pipeline progress highlights are frequent

AstraZeneca's 2022Q3 China revenue was $1.541 billion, up another 8%! Pipeline progress highlights are frequent

 Last Update: 2023-01-06
 Source: Internet
 Author: User

Tags

antithrombin 3 high

estrogens total

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On November 10, AstraZeneca released its financial results
for the third quarter of 2022.
During the quarter, AstraZeneca's total revenue was 110 billion dollars, up 19%
year-over-year.
In the first three quarters of this year, AstraZeneca's total revenue reached $33.
1 billion (+37%), of which product revenue accounted for 322%.
US$ (+35%); $7.
137 billion invested in R&D (+4%)
.
(PPT information can be sent to the Insight public account "AstraZeneca.
") 2022" is available for quick download) Based on the successive achievement of cooperation milestones and the strong contribution of the new crown long-acting neutralizing antibody Evusheld, AstraZeneca announced an upward revision for 2022 Annual core earnings per share (EPS) guidance, adjusted from 20% high to 30%
low.
AstraZeneca's performance in the first three quarters of 2022

On November 10, AstraZeneca released its financial results
for the third quarter of 2022.
Total revenue 110 billion, up 19% year-over-year AstraZeneca 2022

Screenshot from: AstraZeneca official website information Unless otherwise mentioned in the following article, the screenshots are from the AZ official website

Revenue overview

In terms of therapeutic areas, the revenue of the anti-tumor segment in the first three quarters (YTD) was 115 US$ (+24%); Biopharma revenue was $15.
1 billion (+21%), with contributions from CVRM, R&I, and V&I $6.
9 billion (+19%), $4.
5 billion (+4%), and $3.
7 billion (+56%); Rare Diseases segment revenue 52 billion dollars
.
The specific revenue situation will be attached at the end of the article, and it will not be repeated
in the article.
In the covid field, AZ's adenovirus vaccine Vaxzevria Like similar products, sales declined, with revenue of $1.
8 billion (-16%), but Evusheld, which was approved late last year, earned $1.
5 billion in revenue and is close to vaccine revenue
.
Q3 Proportion of product revenue in each therapeutic area (left) Specific data and main factors (bottom) Basic data of YTD revenue in each therapeutic area (right)

In terms of therapeutic areas, the anti-tumor plate biopharmaceutical sector rare disease department in the new crown field,

By region, Q3 revenue in China was US$1.
541 billion, up 8% year-on-year; U.
S.
regional revenue increased year-over-year to $4.
65 billion 34%
。

By region, China Q3 revenue was $1.
541 billion, up 8% year-over-year

Regional Q3 revenue with (top) and without COVID vaccines

Sales revenue TOP20 products are basically unchanged
from the middle of the year.

Sales revenue TOP20 products

TOP20 product Q3/YTD revenue and year-over-year changes

Source: AstraZeneca earnings report, collated by Insight

Pipeline change highlights

AstraZeneca's layout in the field of breast cancer is worth mentioning
.
Via ADC drugs Enhertu (DS-8201, duteruzumab) and Dato-DXd, the oral SERD drug camizestrant, the AKT inhibitor capivasertib, and a new generation of PARP inhibitors AZD5305 covers all types of breast cancer and the number of therapeutic lines
.
AZ coverage for breast cancer indications

AstraZeneca's layout in the field of breast cancer is worth mentioning
.

Especially some time ago, small molecule drugs have disclosed positive news one after another, which is expected to bring transformative new therapies to HR-positive breast cancer patients (see Insight Previous Report >> for details).
In the field of breast cancer, AZ lays a "heaven and earth net").

Recently, two breast cancer drugs have been progressed in succession

In the field of lung cancer, AZ also has many
highlights in the research pipeline after the blockbuster osimertinib.
ADC drugs The primary indication for Dato-DXd is NSCLC, an ATR inhibitor developed based on a synthetic lethal mechanism Celarasertib aims to address tumor immunotherapy resistance, and the LATIFY study in combination with PD-L1 duvalumab is expected in 2023 Read out
after the year.
EGFR/c-Met dual-target ADC drug AZD9592 debuted in this earnings report to address osimertinib resistance
.
The project came from AstraZeneca's own ADC platform, rather than an external collaboration
.
AZ expects to launch I in late 2022 to early 2023 Phase clinical
.
New developments in the field of lung cancer at AstraZeneca

In the field of lung cancer, AZ also has many
highlights in the research pipeline after the blockbuster osimertinib.
ADC drugs Dato-DXdATR inhibitors celarasertibEGFR/c-Met dual-target ADC drug AZD9592

Q3 Pipeline changes are still worth paying attention to
.
In the pipeline removal table, more than one new drug in the field of metabolism has changed: PCSK9 oligonucleotide drugs AZD8233 (hypercholesterolemia), GLP-1R/GCGR dual agonist Cotadutide (type 2 diabetes, obesity and diabetic nephropathy) from original II Removed
from the phase clinical pipeline.
Q3 Pipeline progress (above); Q3 Pipeline removal (below)

Q3 Pipeline changes are still worth paying attention to
.

In 2022-2023, AstraZeneca's potential post-pipeline milestones are as follows, with the China section being individually circled in red,

Potential post-pipeline milestones for AstraZeneca in 2022-2023

Potential milestones for 2022-2023

Attachment 1: Revenue in AZ Key Therapeutics Areas

Attachment 2: Detailed revenue trends of key products in the field of oncology

Attachment 3: Revenue from emerging markets including China

Attachment 4: Detailed pipeline appendix

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.